טוען...
Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma
BACKGROUND: Most patients with multiple myeloma (MM) will relapse after an initial response and eventually succumb to their disease. This is due to the persistence of chemotherapy-resistant tumor cells in the patients’ bone marrow (BM) and immunotherapeutic approaches could contribute to eradicating...
שמור ב:
| הוצא לאור ב: | J Transl Med |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4474344/ https://ncbi.nlm.nih.gov/pubmed/26088750 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-015-0562-5 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|